Goldman Sachs initiated coverage of BioAge Labs (BIOA) with a Not Rated. The firm models for peak azelaprag sales of $8.5B in 2036 via peak penetration of 15% into the incretin-treated market.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs initiated with an Overweight at Morgan Stanley
- BioAge Labs initiated with a Buy at Jefferies
- Opening Day: Self-driving startup Pony.ai files for U.S. IPO
- Arcadium confirms Rio approach, Apollo funds to acquire Barnes: Morning Buzz
- Obesity drugmaker Rivus to weigh IPO as soon as this year, Bloomberg says